This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CARLSBAD, Calif., Oct. 1, 2010 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that it will be presenting an update on the company's progress at the William Blair Emerging Growth Stock Conference at the Intercontinental New York Barclay hotel at 9:30 am eastern daylight time on October 5
th 2010. The update will be concurrently webcast and can be accessed via the company's website under the Investor Relations webpage.
GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark's XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.
CONTACT: GenMark Diagnostics, Inc.
Steven Kemper, Chief Financial Officer